18/09/2025
From our friends at Lucid in Santa Barbara
Psychedelics in the News: Progress, Policy, and Perspectives
At Lucid, we believe that staying informed is part of healing. The psychedelic landscape is evolving quickly—new research, policy shifts, and public discussions are shaping the future of care. Here are some of the most important developments this month:
Mississippi Looks at Ibogaine Legislation
Following Texas’ landmark $50 million investment into ibogaine research, Mississippi lawmakers recently held a joint hearing to consider similar steps. Advocates, including veterans and medical professionals, shared testimony on ibogaine’s potential for addressing trauma and addiction. While challenges remain, the growing interest from state legislatures underscores how urgently new tools for healing are needed.
Psilocybin Therapy and Cost-Effectiveness
Psilocybin-assisted therapy (PAT) continues to show promise in clinical trials for depression. But recent analysis in Translational Psychiatry asks: Is it cost-effective?
PAT may offer stronger health benefits than standard treatments, but the upfront cost is higher—estimated at $3,600 more per year than current approaches.
Researchers suggest that if providers can keep costs below $5,000, psilocybin therapy may become an economically viable option.
This highlights the importance of balancing access, affordability, and innovation—something Lucid prioritizes with treatments like Spravato® (esketamine nasal spray), which is FDA-approved, insurance-covered, and proven effective for treatment-resistant depression.
Psilocybin and Longevity—Hope or Hype?
A recent rodent study suggested psilocybin could extend lifespan by slowing cellular aging. However, scientists caution that the effect may simply be linked to appetite suppression—mice treated with psilocin ate less, and calorie restriction is already known to extend lifespan. While the results are intriguing, much more human research is needed before psilocybin can be considered a true “anti-aging” therapy.
Psychedelics in the U.S. Today
5.5 million Americans used psilocybin in the past year, making it the most commonly used psychedelic in the country.
Most people used in small, private settings with friends or family.
Legal battles continue, such as Seattle physician Dr. Sunil Aggarwal’s case for access to psilocybin for terminally ill patients.
In Oregon, regulators issued new rules limiting service centers’ “temporary use” hours to 6am–11:59pm, aiming to reduce risks tied to overnight sessions.
Why This Matters at Lucid
The world is paying attention to psychedelic medicine more than ever before—yet the stigma and confusion around these treatments remain high. At Lucid, we’re proud to provide safe, structured, evidence-based care with FDA-approved Spravato®, ketamine-assisted therapy, and integration support. As these national conversations unfold, our mission stays the same: to help you heal with clarity, compassion, and science-backed solutions.
✨ Curious about how these treatments may support your journey?
Schedule a consultation with our team today to explore whether Spravato® or ketamine therapy is right for you.
📞 (805) 365-4095
📍 Santa Barbara, CA
🔗 Schedule a Consultation
